Do analysts recommend MCRB or COCP?

Seres Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 221.97%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MCRB or COCP more profitable?

Seres Therapeutics' return on equity of -130.29% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% Cocrystal Pharma N/A -150.61% -97.86%

Do analysts recommend TCRT or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TCRT or COCP more profitable?

Cocrystal Pharma's return on equity of -150.61% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Cocrystal Pharma N/A -150.61% -97.86%

Do analysts prefer COCP or MREO?

Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 992.07%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mereo BioPharma Group 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is COCP or MREO more profitable?

Mereo BioPharma Group's return on equity of -81.28% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cocrystal Pharma N/A -150.61% -97.86% Mereo BioPharma Group N/A -81.28% -70.45%

Do analysts recommend MGX or COCP?

Metagenomi presently has a consensus price target of $7.00, suggesting a potential upside of 464.52%. Given Metagenomi's stronger consensus rating and higher possible upside, research analysts plainly believe Metagenomi is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to MGX or COCP?

In the previous week, Metagenomi had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 2 mentions for Metagenomi and 1 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.00 beat Metagenomi's score of -0.28 indicating that Cocrystal Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SCYX or COCP?

SCYNEXIS currently has a consensus price target of $24.00, indicating a potential upside of 506.06%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Cocrystal Pharma (COCP) Competitors

$0.93 +0.00 (+0.10%)

Closing price 03:59 PM Eastern

Extended Trading

$0.93 0.00 (0.00%)

As of 04:10 PM Eastern

Compare

COCP vs. MCRB, TCRT, MREO, MGX, and SCYX

Should you buy Cocrystal Pharma stock or one of its competitors? MarketBeat compares Cocrystal Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cocrystal Pharma include Seres Therapeutics (MCRB), Alaunos Therapeutics (TCRT), Mereo BioPharma Group (MREO), Metagenomi (MGX), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry.

How does Cocrystal Pharma compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

Seres Therapeutics presently has a consensus price target of $17.00, suggesting a potential upside of 221.97%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Seres Therapeutics has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Seres Therapeutics' return on equity of -130.29% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Cocrystal Pharma	N/A	-150.61%	-97.86%

In the previous week, Cocrystal Pharma had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.00 equaled Cocrystal Pharma'saverage media sentiment score.

Company	Overall Sentiment
Seres Therapeutics	Neutral
Cocrystal Pharma	Neutral

Seres Therapeutics has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	64.70	$5.70M	-$5.17	N/A
Cocrystal Pharma	$225K	57.05	-$8.83M	-$0.73	N/A

Summary

Seres Therapeutics beats Cocrystal Pharma on 10 of the 14 factors compared between the two stocks.

How does Cocrystal Pharma compare to Alaunos Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Alaunos Therapeutics has higher earnings, but lower revenue than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	$3K	15,874.30	-$4.18M	-$2.13	N/A
Cocrystal Pharma	$225K	57.05	-$8.83M	-$0.73	N/A

Cocrystal Pharma's return on equity of -150.61% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Cocrystal Pharma	N/A	-150.61%	-97.86%

Alaunos Therapeutics has a beta of -1.02, suggesting that its stock price is 202% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

In the previous week, Cocrystal Pharma had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 0.00 equaled Cocrystal Pharma'saverage media sentiment score.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
Cocrystal Pharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cocrystal Pharma beats Alaunos Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Cocrystal Pharma compare to Mereo BioPharma Group?

Cocrystal Pharma (NASDAQ:COCP) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Cocrystal Pharma has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cocrystal Pharma	$225K	57.05	-$8.83M	-$0.73	N/A
Mereo BioPharma Group	$500K	95.00	-$41.88M	-$0.05	N/A

Cocrystal Pharma has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Mereo BioPharma Group has a consensus target price of $3.25, suggesting a potential upside of 992.07%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Mereo BioPharma Group's return on equity of -81.28% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cocrystal Pharma	N/A	-150.61%	-97.86%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

In the previous week, Cocrystal Pharma had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for Mereo BioPharma Group. Cocrystal Pharma's average media sentiment score of 0.00 equaled Mereo BioPharma Group'saverage media sentiment score.

Company	Overall Sentiment
Cocrystal Pharma	Neutral
Mereo BioPharma Group	Neutral

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Mereo BioPharma Group beats Cocrystal Pharma on 9 of the 14 factors compared between the two stocks.

How does Cocrystal Pharma compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

In the previous week, Metagenomi had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 2 mentions for Metagenomi and 1 mentions for Cocrystal Pharma. Cocrystal Pharma's average media sentiment score of 0.00 beat Metagenomi's score of -0.28 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cocrystal Pharma has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Cocrystal Pharma	N/A	-150.61%	-97.86%

Metagenomi has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

6.7% of Cocrystal Pharma shares are held by institutional investors. 12.5% of Metagenomi shares are held by insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cocrystal Pharma has lower revenue, but higher earnings than Metagenomi. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$22.33M	2.09	-$87.87M	-$2.30	N/A
Cocrystal Pharma	$225K	57.05	-$8.83M	-$0.73	N/A

Metagenomi presently has a consensus price target of $7.00, suggesting a potential upside of 464.52%. Given Metagenomi's stronger consensus rating and higher possible upside, research analysts plainly believe Metagenomi is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Metagenomi beats Cocrystal Pharma on 9 of the 17 factors compared between the two stocks.

How does Cocrystal Pharma compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

SCYNEXIS has higher revenue and earnings than Cocrystal Pharma. Cocrystal Pharma is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	1.91	-$8.61M	-$3.84	N/A
Cocrystal Pharma	$225K	57.05	-$8.83M	-$0.73	N/A

In the previous week, Cocrystal Pharma had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 1 mentions for Cocrystal Pharma and 0 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 0.00 equaled Cocrystal Pharma'saverage media sentiment score.

Company	Overall Sentiment
SCYNEXIS	Neutral
Cocrystal Pharma	Neutral

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cocrystal Pharma has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -57.16% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Cocrystal Pharma	N/A	-150.61%	-97.86%

SCYNEXIS currently has a consensus price target of $24.00, indicating a potential upside of 506.06%. Given SCYNEXIS's stronger consensus rating and higher probable upside, analysts plainly believe SCYNEXIS is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

SCYNEXIS has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Summary

SCYNEXIS beats Cocrystal Pharma on 9 of the 15 factors compared between the two stocks.

Get Cocrystal Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COCP vs. The Competition

Export

Metric	Cocrystal Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.84M	$3.64B	$6.77B	$12.60B
Dividend Yield	N/A	2.18%	2.67%	9.67%
P/E Ratio	-1.28	21.35	26.91	23.97
Price / Sales	57.05	174.30	507.72	91.38
Price / Cash	N/A	150.24	49.71	59.37
Price / Book	2.02	8.00	10.56	6.16
Net Income	-$8.83M	$23.81M	$3.60B	$331.71M
7 Day Performance	-3.02%	-3.23%	-2.15%	-1.94%
1 Month Performance	-6.90%	-0.70%	0.11%	-2.49%
1 Year Performance	-41.81%	41.99%	22.63%	17.28%

Cocrystal Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COCP Cocrystal Pharma	0.3615 of 5 stars	$0.93 +0.1%	N/A	-42.2%	$12.84M	$225K	N/A	10
MCRB Seres Therapeutics	2.7083 of 5 stars	$5.34 -5.0%	$17.00 +218.4%	-62.1%	$51.69M	$790K	N/A	330	High Trading Volume
TCRT Alaunos Therapeutics	0.211 of 5 stars	$2.09 +0.5%	N/A	-32.6%	$51.04M	N/A	N/A	40
MREO Mereo BioPharma Group	1.765 of 5 stars	$0.31 -2.2%	$3.25 +935.0%	-82.1%	$50.12M	$500K	N/A	40
MGX Metagenomi	2.727 of 5 stars	$1.32 flat	$7.00 +430.3%	-43.8%	$49.70M	$25.21M	N/A	236	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COCP) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cocrystal Pharma (COCP) Competitors

COCP vs. MCRB, TCRT, MREO, MGX, and SCYX

How does Cocrystal Pharma compare to Seres Therapeutics?

Summary

How does Cocrystal Pharma compare to Alaunos Therapeutics?

Summary

How does Cocrystal Pharma compare to Mereo BioPharma Group?

Summary

How does Cocrystal Pharma compare to Metagenomi?

Summary

How does Cocrystal Pharma compare to SCYNEXIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cocrystal Pharma (COCP) Competitors

COCP vs. MCRB, TCRT, MREO, MGX, and SCYX

How does Cocrystal Pharma compare to Seres Therapeutics?

Do analysts recommend MCRB or COCP?

Which has more volatility & risk, MCRB or COCP?

Do institutionals & insiders hold more shares of MCRB or COCP?

Is MCRB or COCP more profitable?

Does the media prefer MCRB or COCP?

Which has higher earnings and valuation, MCRB or COCP?

Summary

How does Cocrystal Pharma compare to Alaunos Therapeutics?

Which has preferable valuation and earnings, TCRT or COCP?

Is TCRT or COCP more profitable?

Which has more risk & volatility, TCRT or COCP?

Does the media refer more to TCRT or COCP?

Do analysts recommend TCRT or COCP?

Do insiders and institutionals have more ownership in TCRT or COCP?

Summary

How does Cocrystal Pharma compare to Mereo BioPharma Group?

Which has stronger valuation and earnings, COCP or MREO?

Which has more risk & volatility, COCP or MREO?

Do analysts prefer COCP or MREO?

Is COCP or MREO more profitable?

Does the media favor COCP or MREO?

Do insiders and institutionals hold more shares of COCP or MREO?

Summary

How does Cocrystal Pharma compare to Metagenomi?

Does the media refer more to MGX or COCP?

Is MGX or COCP more profitable?

Which has more risk and volatility, MGX or COCP?

Do institutionals & insiders hold more shares of MGX or COCP?

Which has stronger valuation & earnings, MGX or COCP?

Do analysts recommend MGX or COCP?

Summary

How does Cocrystal Pharma compare to SCYNEXIS?

Which has higher earnings and valuation, SCYX or COCP?

Does the media refer more to SCYX or COCP?

Do institutionals and insiders believe in SCYX or COCP?

Is SCYX or COCP more profitable?

Do analysts prefer SCYX or COCP?

Which has more volatility and risk, SCYX or COCP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP vs. The Competition

Cocrystal Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools